Skip to main content

Advertisement

SpringerLink
Log in

Progress in Mechanism of Astragalus membranaceus and Its Chemical Constituents on Multiple Sclerosis

  • Review
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

The primary chemical components of Astragalus membranaceus include polysaccharides, saponins, flavonoids, and amino acids. Recent studies have shown that Astragalus membranaceus has multiple functions, including improving immune function and exerting antioxidative, anti-radiation, anti-tumor, antibacterial, antiviral, and hormone-like effects. Astragalus membranaceus and its extracts are widely used in clinical practice because they have obvious therapeutic effects against various autoimmune diseases and relatively less adverse reaction. Multiple sclerosis (MS) is an autoimmune disease of central nervous system (CNS), which mainly caused by immune disorder that leads to inflammatory demyelination, inflammatory cell infiltration, and axonal degeneration in the CNS. In this review, the authors analyzed the clinical manifestations of MS and experimental autoimmune encephalomyelitis (EAE) and focused on the efficacy of Astragalus membranaceus and its chemical components in the treatment of MS/EAE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mimpen M, Smolders J, Hupperts R, et al. Natural killer cells in multiple sclerosis: a review. Immunol Lett 2020;222:1–11.

    Article  CAS  Google Scholar 

  2. Centonze D, Leocani L, Feys P. Advances in physical rehabilitation of multiple sclerosis. Curr Opin Neurol 2020;33:255–261.

    Article  Google Scholar 

  3. Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis risk factors, prodromes and potential causal pathways. Lancet Neurol 2010;9:727–739.

    Article  Google Scholar 

  4. Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity/work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 Update. Arch Physical Med Rehabil 2020;102:115–131.

    Article  Google Scholar 

  5. Johan H, Anette R, Kristina K. Rituximab in multiple sclerosis at general hospital level. Acta Neurol Scandinavica 2020;141:491–499.

    Article  Google Scholar 

  6. Anisha S, Jeremy C. Multiple sclerosis, a treatable disease. Clin Med 2016;16 (Suppl 6):s53–s59.

    Google Scholar 

  7. Perry M, Swain S, Kemmis-Betty S, et al. Multiple sclerosis: summary of NICE guidance. Br Med J 2014;349:g5701.

    Article  Google Scholar 

  8. Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol 2015;15:273.

    Article  Google Scholar 

  9. Wollebo HS, White M, Gordon J, et al. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 2015;77:560–570.

    Article  Google Scholar 

  10. Valenzuela RM, Pula J, Garwacki D, et al. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J Neurol Sci 2014;340:109–111.

    Article  Google Scholar 

  11. Lehmann HC, Kruger K, Fink GR, et al. Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy. J Neurol 2015;262:771–773.

    Article  Google Scholar 

  12. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Eng J Med 2010;362:387–401.

    Article  CAS  Google Scholar 

  13. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Eng J Med 2015;372:1476–1478.

    Article  CAS  Google Scholar 

  14. Min MX, Weinberg D, McCabe RP. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. J Clin Pharm Ther 2014;39:107–111.

    Article  CAS  Google Scholar 

  15. Wang Y, Lin XM, Zheng GQ. Traditional Chinese medicine for Parkinson’s disease in China and beyond. J Altern Complement Med 2011;17:385–388.

    Article  Google Scholar 

  16. Peng Y, Yang SS, Gan L, et al. Focus on Chinese herbal medicine therapy for multiple sclerosis by dialectical treatment. Chin Med J (Eng) 2021;134:278–233.

    Article  CAS  Google Scholar 

  17. Wang LH, Zhang Y, Lan K, et al. Inhibitory effect of astragalus polysaccharides on pulmonary inflammation in asthma model mice and its mechanism. J Jilin Univ (Med Edit, Chin) 2019;45:313–318.

    Google Scholar 

  18. Zhou X, Liu ZJ, Long TT. Immunomodulatory effects of herbal formula of astragalus polysaccharide (APS) and polysaccharopeptide (PSP) in mice with lung cancer. Int J Biol Macromolecules 2018;106:596–601.

    Article  CAS  Google Scholar 

  19. Nie W, Peng Y, Zhao L, et al. The role of Huangqi Guizhiwuwu Decoction on autoimmune disease. Hunan J Tradit Chin Med (Chin) 2019;35:171–173.

    Google Scholar 

  20. Cui SQ. Effect of trimetazidine combined with Huangqi Injection on resisting inflammation and oxygen radicals in patients with acute viral myocarditis. J Hainan Med Univ (Chin) 2018;24:737–739.

    CAS  Google Scholar 

  21. Liu DL, Bao HY, Liu Y. Progress on chemical constituents and pharmacological effects of Astragali Radix in recent five years. Food Drug 2014;16:68–70.

    CAS  Google Scholar 

  22. Hu XL. Studies on the extraction, and purification of Astragalus glycoprotein and analysis on its struction and immune inhibition activity [dissertation]. Taiyuan: Shanxi University; 2013.

    Google Scholar 

  23. Ma W, Li HY, He X, et al, Research progress of anti-aging effect of Astragalus membranaceus. J Liaoning Univ Tradit Chin Med (Chin) 2020;22:4.

    Google Scholar 

  24. Liu Q, Fan Y, Li X, et al. Effect and mechanism of Astragali Radix—Puerariae Lobatae Radix compatibility on glucose-lipid and inflammatory of diabetes rats. Chin J Exp Tradit Med Formul (Chin) 2018;24:81–86.

    Google Scholar 

  25. Tian H, Deng YR, Zhou K, et al. Chemical constituents of Astragalus membranaceus var. mongholicus. Chin J Exp Tradit Med Formul (Chin) 2016;22:70–73.

    CAS  Google Scholar 

  26. Yu L, Wang ZB, Wang QH, et al. Research progress on pharmacological effects of flavonoids in Astragali Radix. Inform Tradit Chin Med (Chin) 2018;35:104–108.

    Google Scholar 

  27. Wu J, Wang C. Research progress on chemical constituents and pharmacology of Astragalus. J Xinxiang Med Univ (Chin) 2018;35:755–760.

    Google Scholar 

  28. Hartung HP, Graf J, Aktas O, et al. Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017—continuity and change. Curr Opin Neurol 2019;32:327–337.

    Article  Google Scholar 

  29. Peng Y, Gan L, Li SP, et al. Research progress of myelin antigen specific CD8+ T cells in immune immunity of MS/EAE brain tissue. J Int Neurol Neurosurg 2018;45:532–535.

    Google Scholar 

  30. Li JJ, Li J, Han MX. Effect of Yishen Busui Tongluo Decoction with methylprednisolone on multiple sclerosis and its effect on the expression of inflammatory factors and HMGB1. Modern J Integr Tradit Chin West Med (Chin) 2019;28:4012–4016.

    Google Scholar 

  31. Peng Y, Deng X, Zeng QM, et al. Current autoimmune diseases research highlights: evidence for Tc17 cells. Chin Med J (Engl) 2022; in press.

  32. Balasa R, Barcutean L, Balasa A, et al. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Human Immunol 2020;81:237–243.

    Article  CAS  Google Scholar 

  33. Peng Y, Gan L, Chen ZX, et al. Effect of antigen-presenting cells on myelin specific T cell reactivation in the central nervous system. J Int Neurol Neurosurg 2019;46:439–442.

    Google Scholar 

  34. Zhang DY, Jin WD, Liu HL, et al. ENT1 inhibition attenuates apoptosis by activation of cAMP/pCREB/Bcl2 pathway after MCAO in rats. Exp Neurol 2020;331:113362.

    Article  CAS  Google Scholar 

  35. You YZ. Study on FMRI evaluating repair and regeneration of myelin sheath, axon and nerve fiber of tonifying the Kidney treating multiple sclerosis patients [dissertation]. Beijing: Beijing University of Chinese Medicine; 2014.

    Google Scholar 

  36. Zheng QL, Chu SF, Xu X, et al. Research progress on the neuroprotective effects of Astragaloside. Chin J Phamacol Toxicol (Chin) 2019;33:877.

    Google Scholar 

  37. Zhang JL, Li YY, Yang WL, et al. Astragaloside IV protect PC12 cells under stress induced by oxygen-glucose deprivation involving PI3K/Akt/Bcl-2 pathway. Acta Neuropharmacologica 2017;136:1–8.

    Google Scholar 

  38. Huang XP, Ouyang G, Ding H, et al. Effects of astragaloside IV combined with active components of Panax notoginseng on apoptosis and endoplasmic reticulum stress in brain tissues after cerebral ischemia-reperfusion in mice. Chin Tradit Herb Drugs (Chin) 2015;46:8.

    Google Scholar 

  39. Höftberger R, Yong G, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 2020;139:875–892.

    Article  Google Scholar 

  40. Zhang Z, Chen WL. Advances in the study of oligodendrocytes in neurodegenerative diseases. J Yunan Univ: Natl Sci Edit (Chin) 2019;41:404–410.

    Google Scholar 

  41. Xing YX, Liu BY, Zhao YJ, et al. Neuroprotective effect and repair mechanism of Huangqi glycoprotein on mice with experimental autoimmune encephalomyelitis. Chin J Exp Tradit Med Formul (Chin) 2018;24:7–13.

    Google Scholar 

  42. Xing YX, Li ZQ, Liu BY, et al. Protective effect of Astragalus polysaccharides on acute demyelination model induced by CPZ. Chin J Gerontol (Chin) 2020;40:834–839.

    CAS  Google Scholar 

  43. Xu W, Wang GP. Diagnosis and treatment of multiple sclerosis. Chin General Pract (Chin) 2019;17:1437–1438.

    Google Scholar 

  44. Wang Y, Li WY, Liu GB, et al. Recovery effects of astragaloside VI combined with adipose tissue-derived stem cell transplantation on motor function of rats after sciatic nerve defects. Shandong Med J (Chin) 2013;53:4–6.

    Google Scholar 

  45. Li JM, Chen WR. Clinical efficacy of modified Huagnqi Chifeng Decoction and Dihuang Decoction to repair damaged nerve function in patients with ischemic stroke convalescence. World Chin Med(Chin) 2019;14:3000–3004.

    Google Scholar 

  46. Yin YY, Li WP, Gong HL, et al. Protective effect of astragaloside on focal cerebral ischemia/reperfusion injury in rats. Am J Chin Med 2010;38:517–527.

    Article  CAS  Google Scholar 

  47. Jang SY, Yayeh T, Leem YH, et al. Concanavalin A induces cortical neuron apoptosis by causing ROS accumulation and tyrosine kinase activation. Neurochem Res 2017;42:3504–3514.

    Article  CAS  Google Scholar 

  48. Wang XQ, Tian QQ, Li YH, et al. Immunoregulatory effect of Buyang Huanwu Decoction on experimental autoimmune encephalomyelitis mice. Chin J Immunol (Chin) 2017;1:52–57.

    Google Scholar 

  49. Bian XJ, Wang XH. Effects of modified Huangqi Guizhi Wuwu Decoction on serum MDA and GSH levels in diabetic peripheral neuropathy rats. J Shandong Univ Chin Med (Chin) 2010;34:78–79.

    Google Scholar 

  50. Zhang XZ, Cheng T, Kou HW, et al. Effect of Astragalus membranaceus on nerve repair in mice with spinal cord injury. Chin J Exp Surg (Chin) 2019;4:718–721.

    Google Scholar 

  51. Kim H, Lee J, Choi M. Ethanolic extract of Astragali Radix and Salviae Radix prohibits oxidative brain injury by psycho-emotional stress in whisker removal rat model. PLoS One 2014;9:e98329.

    Article  Google Scholar 

  52. Lu LY, Li M, Xie J. Protective effect of Astragaloside IV on focal cerebral ischemia-reperfusion injury in rats. Pharm Care Res 2017;17:392–396.

    Article  Google Scholar 

  53. Wang M, Huang RZ, Zheng F, et al. Clinical pharmacology of Astragalus membranaceus in the treatment of cardiovascular diseases. Prev Treat Cardiovasc Dis 2019;9:55–57.

    Google Scholar 

  54. Jiang RF, Li LH, Ling ZG, et al. Study on role mechanism of Astragalus membranaceus extract in treating infected mice with respirator syncytial virus. Prog Modern Biomed (Chin) 2019;19:2081–2085.

    Google Scholar 

  55. Yang XH, Xiao YF, Liu TL, et al. Effects of astragaloside on repair of Coxsackie B virus type 3 virus-infected neonatal rat cardiomyocytes and viral myocarditis neonatal rat cardiomyocytes. Shandong Med J (Chin) 2019;59:48–52.

    Google Scholar 

  56. Zhang JJ, Zhong J, Zhang SJ, et al. Effects of calycosin on permeability and MLC phosphrylation of HUVEC infected with influenza virus. Chin Arch Tradit Chin Med (Chin) 2019;37:1368–1372.

    CAS  Google Scholar 

  57. Peng Y, Deng X, Zhou JX, et al. Experimental autoimmune encephalomyelitis inhibited by Huangqi Guizhi Wuwu Decoction via Th2 cytokine enhancement. World J Tradit Chin Med (Chin) 2021;7:467–476.

    Article  CAS  Google Scholar 

  58. Peng Y, Zhu FZ, Chen ZX, et al. Characterization of myelin oligodendrocyte glycoprotein (MOG)35-55-specific CD8+ T cells in experimental autoimmune encephalomyelitis. Chin Med J (Eng) 2019;132:2934–2940.

    Article  CAS  Google Scholar 

  59. Mi XT, Zhang PJ, Wang J. Research progress of astragalus glycoprotein in multiple sclerosis. J Shanxi Datong Univ (Nat Sci Edit, Chin) 2018;34:39–42.

    Google Scholar 

  60. Yang CY, Li YH, Xin YL, et al. The effect of Astragalosides on treating multiple sclerosis. J Shanxi Datong Univ (Nat Sci Edit, Chin) 2016;32:48–53.

    CAS  Google Scholar 

  61. Zhang DW. Clinical study on Huangqi Injection combined with methylprednisolone in treatment of multiple sclerosis. Drugs Clin (Chin) 2016;31:517–520.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan Province, 412000, China

    Yong Peng, Xiang Deng, Shan-shan Yang, Wei Nie & Yan-dan Tang

Authors
  1. Yong Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiang Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shan-shan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan-dan Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Peng Y received funding support and developed the research hypotheses. Peng Y, Deng X, Yang SS, Nie W and Tang YD wrote the manuscript. The final manuscript is the end product of the joint writing efforts of all the authors.

Corresponding author

Correspondence to Yong Peng.

Ethics declarations

The authors have no conflicts of interests to declare.

Additional information

Supported by Creative Research Group of Affiliated First Hospital of Hunan Traditional Chinese Medical College, China (No. 2021B-003), Key Plans of Hunan Administration of Traditional Chinese Medicine, China (No. 201915), Natural Science Foundation of Hunan Province, China (No. 2018JJ6043), Health and Family Planning Commission of Hunan Province, China (No. B20180815), Technology Plan Project of Zhuzhou City, Hunan Province, China (No. 2021-009)

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, Y., Deng, X., Yang, Ss. et al. Progress in Mechanism of Astragalus membranaceus and Its Chemical Constituents on Multiple Sclerosis. Chin. J. Integr. Med. 29, 89–95 (2023). https://doi.org/10.1007/s11655-022-3535-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-022-3535-6

Keywords

Search

Navigation